Physician

Melinda Sue Dunlap, MD

According to 2025 Medicare claims, Melinda Dunlap, MD (NPI: 1609096668) practices medical oncology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (NPI: 1962876045; TIN: 383983999) and primary practice location at 74146-6236.

Dunlap's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,056 traditional Medicare patients, billed 182,294 HCPCS/CPT codes, and received $2,867,258 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,572 prescription claims across 371 beneficiaries totaling $4,642,108 in drug costs, led by Revlimid (Lenalidomide). DME data shows 56 claims. Open Payments data shows 23 records totaling $35,228. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $942,423 to $4,642,108. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $9,319 to $4,350.